California-based biotechnology company Bitterroot Bio has announced the signing of a multi-year research collaboration agreement with China’s Biotheus Inc. The partnership aims to explore the development of innovative drugs that modulate the immune system and inflammatory responses, with a specific focus on targeting cardiovascular diseases (CVDs).
By combining Bitterroot’s knowledge in the CVD field with Biotheus’ proficiency in designing novel protein drugs, the collaboration will initially focus on researching potential drug candidates to address atherosclerosis, among other CVDs. The initial phase of the partnership involves identifying promising candidates for preclinical and clinical studies, with the financial details of the agreement not being publicly disclosed.- Flcube.com
